Clene Inc (CLNN) Stock Price, Quote & News

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods

Sector: Consumer Defensive

Phone: 801 676 9695

Website: clene.com

Address:

6550 South Millrock Drive, Suite G50, Salt Lake City, United States

ChartChartist Oct. 5 at 1:30 AM

$PAVS Agreed. Bid to absorb $WETO wonderful $AGRI coming back $CLNN congrats so fat wow

0 · Reply

josh77 Oct. 4 at 10:19 PM

$CLNN not selling!!

1 · Reply

PennyMan2029 Oct. 4 at 8:54 PM

$CLNN

0 · Reply

highnihilism Oct. 4 at 8:18 PM

$CLNN Clene volume 342,881 | average 95,525 × 3.6 | price 10.51 +2.50 (+31.2%) earnings 08-14-25 bmo

0 · Reply

Takeover24 Oct. 4 at 7:27 PM

$CLNN The one scenario none of us are talking about is the possibility of a full acquisition at this point. While unlikely, it is not inconceivable that a big pharma co would step in at this point and buy them out. Perhaps they have been waiting to see the new data and how things progress with the FDA? But given the building blocks in place, I would say it is a non-zero possibility that someone could take this approach (especially given the challenges of partnering for just one indication based on the trade secret nature of manufacturing etc). This would then beg the question at what price could they get this done. Perhaps $500M (5x from current share price) does it? Who says no to this? While I certainly believe there is far greater upside in the long term, hard not to take a 5x multiple from here and put the $$$ in the bank? Just some additional fun food for thought while we wait to see what Monday brings.

1 · Reply

StockScanners Oct. 4 at 2:38 PM

$CLNN keep watch if this holds above 9.25

0 · Reply

GJ_Rockabilt Oct. 4 at 2:34 PM

$CLNN For a whole year, +110% seems reasonable. No?

0 · Reply

Mulhollandr Oct. 4 at 1:15 PM

$CLNN Dream scenario: Monday - FDA clearance for NDA submission -simultaneously Clene announces major MS financial partner 🚀🚀🚀 I mean, it doesn’t hurt to dream. 😂

2 · Reply

Daf88 Oct. 4 at 7:53 AM

$CLNN I see many wondering about the reason for the spike, but I guess this release 4 days ago was enough isn’t it? https://invest.clene.com/news-releases/news-release-details/clene-presents-new-clinical-data-ectrims-2025-meeting

2 · Reply

WallStreetBuyDip Oct. 4 at 1:45 AM

following my system for $CLNN - only buying when H% is low like shown

0 · Reply

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Sep 4, 2025, 8:30 AM EDT - 4 weeks ago

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:38 AM EDT - 7 weeks ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 13, 2025, 8:00 AM EDT - 7 weeks ago

Clene to Present at the Emerging Growth Conference

Aug 5, 2025, 8:30 AM EDT - 2 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Jun 30, 2025, 8:00 AM EDT - 3 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 9, 2025, 9:00 AM EDT - 4 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 7, 2025, 8:00 AM EDT - 5 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Apr 1, 2025, 8:30 AM EDT - 6 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 8:00 AM EDT - 6 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 12, 2025, 8:00 AM EDT - 7 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 6, 2025, 8:30 AM EST - 7 months ago

Clene to Present at the 37TH Annual Roth Conference

Feb 27, 2025, 9:15 AM EST - 7 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 25, 2025, 8:00 AM EST - 7 months ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Dec 10, 2024, 8:30 AM EST - 10 months ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Feb 29, 2024, 8:00 AM EST - 1 year ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Dec 21, 2023, 11:25 AM EST - 1 year ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 14, 2023, 8:36 AM EST - 1 year ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Nov 7, 2023, 8:00 AM EST - 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Aug 30, 2023, 8:20 AM EDT - 2 years ago

Clene to Present at Upcoming September Conferences

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Jun 21, 2023, 9:20 AM EDT - 2 years ago

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Jun 16, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Pricing of $40 Million Public Offering

Jun 15, 2023, 4:38 PM EDT - 2 years ago

Clene Announces Launch of Proposed Public Offering

ChartChartist Oct. 5 at 1:30 AM

$PAVS Agreed. Bid to absorb $WETO wonderful $AGRI coming back $CLNN congrats so fat wow

0 · Reply

josh77 Oct. 4 at 10:19 PM

$CLNN not selling!!

1 · Reply

PennyMan2029 Oct. 4 at 8:54 PM

$CLNN

0 · Reply

highnihilism Oct. 4 at 8:18 PM

$CLNN Clene volume 342,881 | average 95,525 × 3.6 | price 10.51 +2.50 (+31.2%) earnings 08-14-25 bmo

0 · Reply

Takeover24 Oct. 4 at 7:27 PM

1 · Reply

StockScanners Oct. 4 at 2:38 PM

$CLNN keep watch if this holds above 9.25

0 · Reply

GJ_Rockabilt Oct. 4 at 2:34 PM

$CLNN For a whole year, +110% seems reasonable. No?

0 · Reply

Mulhollandr Oct. 4 at 1:15 PM

$CLNN Dream scenario: Monday - FDA clearance for NDA submission -simultaneously Clene announces major MS financial partner 🚀🚀🚀 I mean, it doesn’t hurt to dream. 😂

2 · Reply

Daf88 Oct. 4 at 7:53 AM

2 · Reply

WallStreetBuyDip Oct. 4 at 1:45 AM

following my system for $CLNN - only buying when H% is low like shown

0 · Reply

Takeover24 Oct. 4 at 1:37 AM

$CLNN Looks like 900,000 shares traded in after hours. It finished up slightly but what does everyone make of ~2x the number of shares traded in AH on a Friday as compared to normal trading? And the AH volume was ~10x the average trading day's volume.

2 · Reply

ransoms2121212 Oct. 4 at 12:31 AM

$CLNN only a birds fan for one weekend, s/o @Mulhollandr

2 · Reply

WallStreetBuyDip Oct. 3 at 11:11 PM

Comparing trending tickers $CLNN vs $AI: CLNN is currently trading at $10.51, though the percentage change isn't specified, and volume data is missing. Meanwhile, AI is at $19.16, also without defined percentage changes or volume figures. Without these specifics, it's tricky to compare their market momentum directly, but clearly, both stocks are actively trading. The actual price of AI is higher, yet without volume and percentage data, it's hard to gauge which has the stronger movement or investor interest today.

0 · Reply

WallStreetBuyDip Oct. 3 at 10:59 PM

Comparing trending tickers $CLNN vs $AI: CLNN holding steady at $10.51 today, though the volume figures remain unclear. On the other hand, AI is priced at $19.16, also without a defined percentage change or specific volume data available. Without these details, it's challenging to directly compare their market movements today, but both stocks seem to be maintaining their current price levels amid unspecified trading activity.

0 · Reply

WallStreetBuyDip Oct. 3 at 10:46 PM

Comparing trending tickers $META vs $CLNN: META is trading at $710.56, but the percentage change isn't specified, nor is the trading volume. CLNN, on the other hand, is at $10.51 with similar details missing. Without percentage changes or specific volume data, it's tough to directly compare their market performances today. Both stocks are active, but we're missing some key data to fully gauge the momentum or investor reactions.

0 · Reply

WallStreetBuyDip Oct. 3 at 10:35 PM

Comparing trending tickers $META vs $CLNN: META is trading at $710.56, which is notable but without a specific percentage change, paired with unclear volume data. Meanwhile, CLNN stands at $10.51, also missing a percentage change and volume specifics. Without exact figures, it's tough to measure their momentum against each other accurately. However, the significant price difference suggests META operates on a much larger financial scale compared to CLNN.

2 · Reply

sliceofbytes Oct. 3 at 9:04 PM

$CLNN on no news, very interesting...

0 · Reply

josh77 Oct. 3 at 8:52 PM

$CLNN will hold until $50!

0 · Reply

Mark_Venture Oct. 3 at 8:51 PM

$CLNN and $NGENF having a stellar day! As someone crippled by MS, I can't wait to take both of them. I imagine I'll feel like Steve Rogers getting the super soldier serum ;)

3 · Reply

DaBullRunner Oct. 3 at 8:43 PM

$CLNN there it goes….. MSPR adding for the BIG run 🚨🚨🚨 WATCH AND LEARN LIKE HIM👇

0 · Reply

Ryan4vp Oct. 3 at 8:38 PM

$CLNN id be very leery of another offering coming. they are negative in cash flow and thats always a bad sign. congrats to those who made a run! might be time to consider getting out a high percentage and lock profits and hold a smaller position and see what happens.

2 · Reply

josh77 Oct. 3 at 8:37 PM

$CLNN wow! Thank you the support CLNN FAMILY

1 · Reply

Market Cap	105.84M
Revenue (ttm)	340,000.00
Net Income (ttm)	-39.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11,588.24%
Debt to Equity Ratio	-0.54

Volume	586,000
Avg Vol	109,688
Day's Range	N/A - N/A
Shares Out	10.07M
Stochastic %K	99%
Beta	0.62
Analysts	Strong Sell
Price Target	$30.43